Question 1

What is Continuity Biosciences?

Accepted Answer

Continuity Biosciences is a Entity.

Question 2

How often does Continuity Biosciences appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 12 articles.

Question 3

When was Continuity Biosciences first tracked by Ergen?

Accepted Answer

First tracked on May 20, 2026.

Question 4

When was Continuity Biosciences last mentioned in news?

Accepted Answer

Last active on Jul 30, 2026.

Question 5

What is Continuity Biosciences's current news sentiment?

Accepted Answer

Aggregate sentiment score: 40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Continuity Biosciences in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Continuity Biosciences?

Accepted Answer

Continuity Biosciences starts pancreatic cancer trial (May 20, 2026, 6 articles).

Question 8

How did the "Continuity Biosciences starts pancreatic cancer trial" event impact Continuity Biosciences?

Accepted Answer

Continuity Biosciences initiated a Phase I clinical trial for its iontophoretic oncology platform (IOP) to treat pancreatic cancer, which could significantly advance its drug delivery technology and potential market value.

Question 9

How did the "Continuity Biosciences appoints Vicky Papoutsis" event impact Continuity Biosciences?

Accepted Answer

Continuity Biosciences appointed Vicky Papoutsis to its Board, strengthening its strategic partnering capabilities as it advances clinical programs.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.